A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - A randomized, multi-center, non-inferiority, phase IV clinical study - Articles - Pneumology

RECOMMENDED

Asthma

Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study

★ 3 Recommended by Dr Martin Frey, Faculty Member

Lancet Respir Med.

van Zyl-Smit RN, Krüll M, Gessner C, Gon Y, Noga O, Richard A, de Los Reyes A, Shu X, Pethe A, Tanase AM, D'Andrea P, PALLADIUM trial investigators.

doi: 10.1016/S2213-2600(20)30178-8.

Diagnosis and management of asthma - Statement on the 2015 GINA Guidelines

Horak F, Doberer D, Eber E, Horak E, Pohl W, Riedler J, Szépfalusi Z, Wantke F, Zacharasiewicz A, Studnicka M

RECOMMENDED

Asthma

Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

★ 3 Recommended by Dr Martin Frey, Faculty Member

Lancet Respir Med.

Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P, IRIDIUM trial investigators.

doi: 10.1016/S2213-2600(20)30190-9.

RECOMMENDED

Asthma

Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)

★ 2 Recommended by Dr Martin Frey, Faculty Member

Respir Med.

Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krüll M, Salina A, Gupta P, Bostel S, Fucile S, Conde LG, Pfister P

doi: 10.1016/j.rmed.2020.106021.

COMMENTED

Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial

Respirology.

Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, Hamann AM, Backer A, Olsson P, Kostikas K, Diaz DV, FLASH Investigators

doi: 10.1111/resp.13374.

RECOMMENDED

Asthma

A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids

★ 2 Recommended by Dr Martin Frey, Faculty Member

Respir Res.

Kerwin E, Pascoe S, Bailes Z, Nathan R, Bernstein D, Dahl R, von Maltzahn R, Robbins K, Fowler A, Lee L

doi: 10.1186/s12931-020-01400-5.

COPD

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study

Respir Res.

Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA

doi: 10.1186/s12931-018-0724-0.

Improving efficiency of pediatric emergency asthma treatment by using metered dose inhaler

J Asthma.

Abaya R, Delgado EM, Scarfone RJ, Reardon AM, Rodio B, Simpkins D, Mehta V, Hayes K, Zorc JJ

doi: 10.1080/

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial

Read the comment: Effectiveness trials in asthma: time to SaLSA? >>>

doi: 10.1016/

Related content

Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study

Diagnosis and management of asthma - Statement on the 2015 GINA Guidelines

Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)

Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial

A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study

Improving efficiency of pediatric emergency asthma treatment by using metered dose inhaler

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial